Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have earned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.00.

Several analysts have issued reports on the stock. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 19th. ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 21st. Stifel Nicolaus reissued a “hold” rating and issued a $5.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, June 25th. HC Wainwright assumed coverage on shares of Keryx Biopharmaceuticals in a research note on Thursday, June 28th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd.

NASDAQ KERX traded up $0.07 during trading on Friday, hitting $2.94. The stock had a trading volume of 21,096 shares, compared to its average volume of 620,184. The company has a debt-to-equity ratio of -3.16, a current ratio of 2.28 and a quick ratio of 1.40. The company has a market cap of $360.17 million, a P/E ratio of -3.24 and a beta of 2.50. Keryx Biopharmaceuticals has a one year low of $2.86 and a one year high of $8.07.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 EPS for the current year.

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of Keryx Biopharmaceuticals during the first quarter worth approximately $201,000. Meridian Wealth Management LLC purchased a new position in shares of Keryx Biopharmaceuticals during the first quarter worth approximately $203,000. Mackay Shields LLC purchased a new position in shares of Keryx Biopharmaceuticals during the first quarter worth approximately $294,000. Summit Trail Advisors LLC increased its position in shares of Keryx Biopharmaceuticals by 355.3% during the first quarter. Summit Trail Advisors LLC now owns 333,803 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 260,485 shares during the period. Finally, Shufro Rose & Co. LLC increased its position in shares of Keryx Biopharmaceuticals by 26.1% during the second quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 19,000 shares during the period. 59.53% of the stock is currently owned by institutional investors and hedge funds.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Article: Stock Symbols and CUSIP Explained

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.